CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $4.65B, above the global median of $1.15B
- PositionCurrent ratio is 27.38×, higher than 95% of its Biotechnology peers (median 5.5×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.65BUSDvs all stocks (USD)
Revenue (TTM)
56.99MUSDvs all stocks (USD)
Profit Margin
-188.15%vs Biotechnology peers
Beta
1.13xvs all stocks
52-Week Change
321.87%vs all stocks
Market Capitalization
4.65BUSDvs all stocks (USD)
Enterprise Value
3.65BUSDvs all stocks (USD)
Forward P/E
-17.84xvs Biotechnology peers
Price to Sales (TTM)
78.96xvs Biotechnology peers
Price to Book (MRQ)
10.18xvs Biotechnology peers
Enterprise to Revenue
64.06xvs Biotechnology peers
Enterprise to EBITDA
-31.64xvs Biotechnology peers
Profit Margin
-188.15%vs Biotechnology peers
Operating Margin
-206.22%vs Biotechnology peers
Return on Assets (TTM)
-20.69%vs Biotechnology peers
Return on Equity (TTM)
-38.42%vs Biotechnology peers
Revenue (TTM)
56.99MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.4580USDUpdated Jul 19, 2026Gross Profit (TTM)
-72.27MUSDvs all stocks (USD)
EBITDA (TTM)
-115.41MUSDvs all stocks (USD)
Net Income (TTM)
-107.23MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-100.00%vs Biotechnology peers
Operating Cash Flow (TTM)
-141.55MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-68.23MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
62.38MUSDFY2025 · Dec 31, 2025Operating Income
-111.29MUSDvs all stocks (USD)
Pre-tax Income
-101.59MUSDFY2025 · Dec 31, 2025Income Tax Expense
4.00KUSDFY2025 · Dec 31, 2025Net Income
-101.59MUSDFY2025 · Dec 31, 2025EBIT
-111.29MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-109.01MUSDFY2025 · Dec 31, 2025Research & Development
132.16MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
41.51MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
5.63MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-101.59MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-135.54MUSDFY2025 · Dec 31, 2025Free Cash Flow
-136.59MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
114.85MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-101.59MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.28MUSDFY2025 · Dec 31, 2025Stock-based Compensation
26.43MUSDFY2025 · Dec 31, 2025Other Non-cash Items
3.88MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
0.00USDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-825.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-65.72MUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.05MUSDFY2025 · Dec 31, 2025Purchase of Investments
-264.46MUSDFY2025 · Dec 31, 2025Sale of Investments
224.64MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-40.87MUSDFY2025 · Dec 31, 2025Other Financing Charges
-36.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
212.36MUSDFY2025 · Dec 31, 2025Shares Outstanding
144.16MSharesUpdated Jul 19, 2026Float Shares
69.56MSharesUpdated Jul 19, 2026Shares Short
42.01MSharesUpdated Jul 19, 2026Short Ratio
6.47daysvs all stocks
Short % of Shares Outstanding
26.10%vs all stocks
% Held by Insiders
1.17%vs all stocks
% Held by Institutions
114.39%vs all stocks
Total Cash (MRQ)
379.84MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.63USDUpdated Jul 19, 2026Total Debt (MRQ)
32.79MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0838xvs Biotechnology peers
Current Ratio (MRQ)
27.38xvs Biotechnology peers
Book Value per Share (MRQ)
2.72USDUpdated Jul 19, 2026Total Assets
398.69MUSDvs all stocks (USD)
Total Current Assets
353.76MUSDFY2025 · Dec 31, 2025Total Liabilities
52.51MUSDFY2025 · Dec 31, 2025Total Non-current Assets
44.93MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
30.83MUSDFY2025 · Dec 31, 2025Total Current Liabilities
21.68MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
112.28MUSDFY2025 · Dec 31, 2025Other Short-term Investments
230.86MUSDFY2025 · Dec 31, 2025Accounts Payable
1.18MUSDFY2025 · Dec 31, 2025Short-term Debt
2.74MUSDFY2025 · Dec 31, 2025Deferred Revenue
0.00USDFY2025 · Dec 31, 2025Other Current Liabilities
1.29MUSDFY2025 · Dec 31, 2025Long-term Debt
30.83MUSDFY2025 · Dec 31, 2025Common Stock (Book)
136.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-603.15MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
346.18MUSDvs all stocks (USD)
52-Week Low
5.77USDUpdated Jul 19, 202652-Week High
34.39USDUpdated Jul 19, 202652-Week Change
321.87%vs all stocks
Beta
1.13xvs all stocks
50-Day MA
26.43USDUpdated Jul 19, 2026200-Day MA
16.38USDUpdated Jul 19, 2026Avg 10-Day Volume
2.78MSharesUpdated Jul 19, 2026Avg 30-Day Volume
5.41MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-0.8300USDUpdated Jul 19, 2026Other Income / Expense
4.07MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 27.38×, higher than 95% of its Biotechnology peers (median 5.5×)Significant
Current ratio: 27.38Industry median: 5.50Industry P95: 22.03Peers compared: 197
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $4.65B, above the global median of $1.15BNotable
Market cap (USD): 4,649,986,375Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Veradermics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Mgi Tech Co Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Crispr Therapeutics AG
Tier 1ProductionApproval-Gated PipelineRule
Ajanta Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai RAAS Blood Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Henlius Biotech, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Simcere Pharmaceutical Group Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Indivior Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRule
LivaNova PLC
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sk Biopharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Relay Therapeutics Inc.
2 interpretationsLow-Leverage Liquidity ConfigurationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Erasca, Inc.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Peric Special Gases Co., Ltd.
1 interpretationLow-Leverage Liquidity Configuration